Open Access Repository

Variation in plasma levels of glucosamine with chronic dosing: A possible reason for inconsistent clinical outcomes in osteoarthritis

Asthana, C ORCID: 0000-0001-6273-2723, Peterson, GM ORCID: 0000-0002-6764-3882, Shastri, M ORCID: 0000-0002-1012-2779, Jones, G ORCID: 0000-0002-9814-0006 and Patel, R ORCID: 0000-0001-9344-1013 2020 , 'Variation in plasma levels of glucosamine with chronic dosing: A possible reason for inconsistent clinical outcomes in osteoarthritis' , Clinical Therapeutics, vol. 42, no. 8 , E140-E149 , doi: 10.1016/j.clinthera.2020.06.009.

Full text not available from this repository.


Purpose:Glucosamine is widely used by patients with osteoarthritis (OA) to provide symptomatic relief and to delay disease progression. However, clinical studies have reported inconsistent clinical outcomes. The current study hypothesized that the reported inconsistent clinical results could be, in part, due to variable bioavailability and elimination of glucosamine. This study therefore aimed to determine steady-state minimum plasma concentrations (Css min) of glucosamine to examine the variability among patients taking the supplement.Methods:Patients with OA who had been taking glucosamine for at least 1 week were recruited. Patients' blood samples were collected 24 h after the ingestion of the previous dose to determine Observed Css min and after a 5-day washout period to determine the endogenous glucosamine levels (GlcNend). The Actual Css min was calculated by using the following equation: Actual Css min = Observed Css min – GlcNend. The glucosamine plasma concentrations were determined by using a previously developed HPLC method.Findings:Ninety-one participants (age range, 42–89 years; mean [SD] age, 68.2 [7.6] years) were recruited (70% females). There was substantial (106-fold) variation, with a 45% coefficient of variation, between the Actual Css min levels (3–320 ng/mL) in participants. No significant association of Actual Css min was observed with various dose- and patient-related variables.Implications:The observed high variability in steady-state plasma concentrations indicates substantial inter-patient differences in the absorption and elimination of glucosamine, which could be a cause for inconsistent clinical outcomes in patients with OA.

Item Type: Article
Authors/Creators:Asthana, C and Peterson, GM and Shastri, M and Jones, G and Patel, R
Keywords: glucosamine, osteoarthritis, pharmacokinetics, plasma concentration, variability
Journal or Publication Title: Clinical Therapeutics
Publisher: Excerpta Medica Inc
ISSN: 0149-2918
DOI / ID Number: 10.1016/j.clinthera.2020.06.009
Copyright Information:

© 2020 Elsevier Inc.

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page